SCHEMBL23720511

SCHEMBL23720511

CC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 1.00
PPARG P37231 8/20 1.00
F7 P08709 7/20 1.00
F3 P13726 7/20 1.00
CYP19A1 P11511 6/20 1.00
PPARD Q03181 6/20 1.00
PPARA Q07869 6/20 1.00
MAPT P10636 5/20 1.00
FFAR1 O14842 5/20 1.00
PTGS1 P23219 4/20 1.00
OXER1 Q8TDS5 4/20 1.00
LMNA P02545 4/20 1.00
ALOX15 P16050 4/20 1.00
HSD17B10 Q99714 4/20 1.00
KMT2A Q03164 3/20 1.00
KDM4E B2RXH2 3/20 1.00
CYP3A4 P08684 3/20 1.00
HPGD P15428 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
L3MBTL1 Q9Y468 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23698169 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698171 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698132 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698219 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698246 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698137 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698164 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698135 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698134 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL23698248 1.00 ALDH1A1 (1.00) ALDH1A1PPARGF7F3CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108713059-A VCN enhancer compositions and methods of use thereof 蓝鸟生物公司 2018-10-26 CN claimed
EP-4654815-A1 UNSATURATED ALDEHYDES VIA RICE BIOTRANSFORMATION Symrise AG (DE) 2025-12-03 EP disclosed
WO-2024156880-A1 UNSATURATED ALDEHYDES VIA RICE BIOTRANSFORMATION SYMRISE AG (DE) 2024-08-02 WO disclosed
WO-2024156360-A1 UNSATURATED ALDEHYDES VIA RICE BIOTRANSFORMATION SYMRISE AG (DE) 2024-08-02 WO disclosed
WO-2023075489-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC SYNDROME-RELATED DISEASES, COMPRISING, AS ACTIVE INGREDIENT, DENDROPANAX TRIFIDUS SAP EXTRACT OR COMPOUND DERIVED THEREFROM 국제뇌교육종합대학원대학교 산학협력단 2023-05-04 WO disclosed
US-20230097753-A1 ALPHA-HYDROXYLATED FATTY-ACID METABOLITES, MEDICAL USES AND USE AS BIOMARKERS UNIVERSITAT DE LES ILLES BALEARS (ES) 2023-03-30 US disclosed
EP-4098649-A2 ALPHA-HYDROXYLATED FATTY-ACID METABOLITES, MEDICAL USES OF SAME AND USE AS BIOMARKERS Universitat de les Illes Balears (ES) 2022-12-07 EP disclosed
CN-115052852-A Alpha-hydroxylated fatty acid metabolites, medical uses thereof, and uses as biomarkers 巴利阿里群岛大学 2022-09-13 CN disclosed
US-20220118064-A1 MULTI-SUPPLEMENT COMPOSITIONS MELALEUCA, INC. 2022-04-21 US disclosed
EP-3973972-A1 MULTI-SUPPLEMENT COMPOSITIONS Melaleuca, Inc. (US) 2022-03-30 EP disclosed
US-11207388-B2 Multi-supplement compositions MELALEUCA, INC. (US) 2021-12-28 US disclosed
EP-3240555-B1 MULTI-SUPPLEMENT COMPOSITIONS MELALEUCA INC (US) 2021-08-04 EP disclosed
CN-108713059-A VCN enhancer compositions and methods of use thereof 蓝鸟生物公司 2018-10-26 CN disclosed
CN-108220246-A For improving the compound of viral transduction 蓝鸟生物公司 2018-06-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11207388-B2 Multi-supplement compositions SLC5A6, FABP2, GLS2 ALDH1A1 2819/4885PPARG 44/4885F7 1163/4885
US-20220118064-A1 MULTI-SUPPLEMENT COMPOSITIONS SLC5A6, FABP2, GLS2 ALDH1A1 2819/4885PPARG 44/4885F7 1163/4885
US-20230097753-A1 ALPHA-HYDROXYLATED FATTY-ACID METABOLITES, MEDICAL USES AND USE AS BIOMARKERS FABP1, CYP27A1, FABP2 ALDH1A1 129/4885PPARG 115/4885F7 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.